secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001601830-23-000065
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roche exercises oncology option under Recursion collaboration; triggers undisclosed fee
--------------------------------------------------------------------------------

- Roche exercised Validated Small Molecule Option for a Small Molecule Validation Program in a single oncology area.
- Option exercised on September 28, 2023; Roche to pay a Validated Small Molecule Option Fee per the agreement.
- This is under the Collaboration and License Agreement between Recursion, Genentech Inc., and F. Hoffmann-La Roche Ltd dated December 5, 2021.
- Fee amount not disclosed; option represents milestone in the existing partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000065/0001601830-23-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000065/rxrx-20230928.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer